PheCheck™ is an investigational device currently in clinical study. It has not been cleared or approved by the FDA and is not available for sale. Participation in the clinical study is limited to enrolled sites.
Resources
Clinical data, patient education, and everything you need to understand PheCheck™ and the science behind it.
Aptatek BioSciences, Inc. Announces Bridge Financing to Support Advancement of the PheCheck™ Aptamer-based In-home Monitoring Platform
Aptatek BioSciences received bridge financing from existing strategic investor Canterbury Scientific, Ltd., building on the continued progress of its PheCheck platform — an FDA Breakthrough Device for at-home phenylalanine monitoring in PKU patients. Canterbury Scientific CEO Clive Seymour said the investment supports commercialization of Aptatek's patient-centric home monitoring approach. CEO Michael Boyce-Jacino credited the funding with strengthening the company's path toward bringing the technology to PKU patients.
Aptatek BioSciences, Inc. Closes Funding Tranche Based on Successful Clinical Evaluation of Its PheCheck™ Aptamer-Based In-Home Monitoring Platform
Aptatek BioSciences closed an additional funding tranche following successful initial clinical evaluation of its PheCheck platform. The round was again led by Canterbury Scientific, Ltd. and the National PKU Alliance (NPKUA), and the funds will go toward completing clinical studies of Aptatek's in-home PKU monitoring platform.
Aptatek BioSciences, Inc. Appoints Seasoned Healthcare Executive Lee McCracken to its Board of Directors
Aptatek BioSciences appointed Lee McCracken, Chairperson of Drawbridge Health and former CEO recruited by GE Ventures and GE Healthcare, as a non-executive director. McCracken brings more than 30 years of pharmaceutical, biotech, diagnostics, device, and venture capital experience, including corporate development, strategic partnering, fundraising, and M&A work at companies such as Allergan and Prometheus Laboratories. He joins Ali Tinazli, PhD, CEO of Lifespin Health, on Aptatek's growing board.
Medical Device Manufacturer, Canterbury Scientific Limited, Completes Investment into Aptatek BioSciences, Inc. Developing Advanced In-Home Monitoring of Chronic Disease
Canterbury Scientific Limited, a New Zealand-based global manufacturer of medical devices, announced it had finalized its investment in Aptatek BioSciences as part of the company's $4 million seed round led by IP Group, Inc. The investment includes an option for Canterbury to manufacture Aptatek's home monitoring device.
Aptatek BioSciences, Inc. Completes $4 Million Seed Funding Led by IP Group, Inc. to Develop Advanced In-Home Monitoring of Chronic Disease
Aptatek BioSciences, based in Princeton, NJ, closed a $4 million seed round led by IP Group, Inc., with participation from Canterbury Scientific Limited and the National PKU Alliance (NPKUA). The funds support clinical validation of Aptatek's first product, an in-home monitoring device for phenylketonuria (PKU), and will help fund new hires as the company explores expanding into chronic kidney disease and medication management.
Aptatek Biosciences Wins “Best in Show” at Philadelphia 1st Pitch Life Science Competition
Mid-Atlantic Bio Angels named Aptatek Biosciences “Best in Show” by audience vote at its 1st Pitch Life Science Philadelphia event, held October 29, 2019 at BakerHostetler's Cira Center offices. CEO Michael Boyce-Jacino, Ph.D., said the company was honored by the recognition and the actionable feedback received, and reaffirmed plans to keep developing the Aptatek-At-Home technology for PKU monitoring.
Aptatek BioSciences, Inc. Receives FDA Breakthrough Device Designation for a Home-Based Test System that Enables Patients to Monitor Blood Levels of Phenylalanine in Real Time
Aptatek BioSciences announced that the FDA's Center for Devices and Radiological Health granted Breakthrough Device designation to its portable PKU (phenylketonuria) test system, which allows patients to measure blood phenylalanine levels at home instead of relying on clinic visits or mailed lab samples. The system pairs with a companion mobile app so users can track changes in their levels over time.